Pelthos Therapeutics Inc.
PTHS
$23.42
-$1.13-4.60%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 717.48% | 858.25% | 617.89% | 493.01% | 3,861.54% |
| Gross Profit | 2,312.23% | 4,763.40% | 2,676.49% | 1,291.57% | -3,861.54% |
| SG&A Expenses | 863.66% | 1,186.83% | 1,100.06% | 1,101.22% | 55.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 872.64% | 1,208.29% | 1,072.81% | 1,011.18% | 83.15% |
| Operating Income | -389.72% | -613.63% | -558.06% | -649.73% | -83.15% |
| Income Before Tax | -578.95% | -1,174.03% | -1,384.22% | -885.43% | -94.68% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -578.95% | -1,174.03% | -1,024.82% | -857.99% | -94.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -578.95% | -1,174.03% | -1,024.82% | -857.99% | -94.68% |
| EBIT | -389.72% | -613.63% | -558.06% | -649.73% | -83.15% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -25.05% | -135.69% | -115.26% | -81.25% | -72.42% |
| Normalized Basic EPS | -17.04% | -135.69% | -181.20% | -86.45% | -72.42% |
| EPS Diluted | -25.05% | -135.69% | -115.26% | -81.25% | -72.42% |
| Normalized Diluted EPS | -17.04% | -135.69% | -181.20% | -86.45% | -72.42% |
| Average Basic Shares Outstanding | 442.95% | 440.54% | 422.53% | 428.57% | 12.90% |
| Average Diluted Shares Outstanding | 442.95% | 440.54% | 422.53% | 428.57% | 12.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |